Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of ERIS LIFESCIENCES. For more details, see the ERIS LIFESCIENCES quarterly results and ERIS LIFESCIENCES share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 1.0 |
No. of shares | m | 136.05 |
1 Week | % | 4.0 |
1 Month | % | 4.0 |
1 Year | % | 43.6 |
52 week H/L | Rs | 971.0/596.2 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
ERIS LIFESCIENCES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 818 | 655 | 644 | 863 | 750 | |
Low | Rs | 572 | 341 | 367 | 577 | 551 | |
Sales per share (Unadj.) | Rs | 71.4 | 79.1 | 89.3 | 99.1 | 123.9 | |
Earnings per share (Unadj.) | Rs | 21.2 | 21.8 | 26.2 | 29.9 | 27.5 | |
Diluted earnings per share | Rs | 21.4 | 21.8 | 26.1 | 29.8 | 27.5 | |
Cash flow per share (Unadj.) | Rs | 23.8 | 25.5 | 29.3 | 34.6 | 36.1 | |
Dividends per share (Unadj.) | Rs | 0 | 2.87 | 5.50 | 6.01 | 7.35 | |
Adj. dividends per share | Rs | 0.00 | 2.86 | 5.49 | 6.00 | 7.35 | |
Avg Dividend yield | % | 0 | 0.6 | 1.1 | 0.8 | 1.1 | |
Book value per share (Unadj.) | Rs | 83.6 | 95.3 | 115.8 | 140.2 | 161.3 | |
Adj. book value per share | Rs | 84.5 | 95.1 | 115.6 | 140.1 | 161.2 | |
Shares outstanding (eoy) | m | 137.52 | 135.78 | 135.78 | 135.93 | 135.99 | |
Price / Sales ratio | x | 9.7 | 6.3 | 5.7 | 7.3 | 5.2 | |
Avg P/E ratio | x | 32.8 | 22.8 | 19.3 | 24.1 | 23.6 | |
P/CF ratio (eoy) | x | 29.2 | 19.5 | 17.2 | 20.8 | 18.0 | |
Price / Book Value ratio | x | 8.3 | 5.2 | 4.4 | 5.1 | 4.0 | |
Dividend payout | % | 0 | 13.1 | 21.0 | 20.1 | 26.7 | |
Avg Mkt Cap | Rs m | 95,518 | 67,649 | 68,637 | 97,846 | 88,446 | |
Total wages/salary | Rs m | 1,907 | 2,057 | 2,293 | 2,502 | 3,462 |
ERIS LIFESCIENCES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 9,822 | 10,741 | 12,119 | 13,470 | 16,851 | |
Other income | Rs m | 317 | 160 | 87 | 261 | 112 | |
Total revenues | Rs m | 10,139 | 10,901 | 12,206 | 13,731 | 16,963 | |
Gross profit | Rs m | 3,451 | 3,679 | 4,307 | 4,850 | 5,369 | |
Depreciation | Rs m | 364 | 503 | 430 | 647 | 1,171 | |
Interest | Rs m | 231 | 23 | 20 | 42 | 263 | |
Profit before tax | Rs m | 3,174 | 3,314 | 3,945 | 4,422 | 4,046 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 262 | 348 | 394 | 364 | 305 | |
Profit after tax | Rs m | 2,911 | 2,965 | 3,551 | 4,058 | 3,742 | |
Gross profit margin | % | 35.1 | 34.3 | 35.5 | 36.0 | 31.9 | |
Effective tax rate | % | 8.3 | 10.5 | 10.0 | 8.2 | 7.5 | |
Net profit margin | % | 29.6 | 27.6 | 29.3 | 30.1 | 22.2 |
ERIS LIFESCIENCES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 6,535 | 5,351 | 5,356 | 7,110 | 8,427 | |
Current liabilities | Rs m | 3,772 | 2,202 | 2,354 | 2,833 | 5,212 | |
Net working cap to sales | % | 28.1 | 29.3 | 24.8 | 31.7 | 19.1 | |
Current ratio | x | 1.7 | 2.4 | 2.3 | 2.5 | 1.6 | |
Inventory Days | Days | 141 | 33 | 109 | 151 | 15 | |
Debtors Days | Days | 31 | 53 | 42 | 44 | 63 | |
Net fixed assets | Rs m | 8,271 | 9,018 | 11,672 | 14,017 | 26,287 | |
Share capital | Rs m | 138 | 136 | 136 | 136 | 136 | |
"Free" reserves | Rs m | 11,356 | 12,799 | 15,589 | 18,928 | 21,796 | |
Net worth | Rs m | 11,493 | 12,935 | 15,724 | 19,064 | 21,932 | |
Long term debt | Rs m | 3 | 0 | 0 | 450 | 6,444 | |
Total assets | Rs m | 14,806 | 14,369 | 17,028 | 21,127 | 34,713 | |
Interest coverage | x | 14.8 | 145.3 | 200.7 | 105.8 | 16.4 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0.3 | |
Sales to assets ratio | x | 0.7 | 0.7 | 0.7 | 0.6 | 0.5 | |
Return on assets | % | 21.2 | 20.8 | 21.0 | 19.4 | 11.5 | |
Return on equity | % | 25.3 | 22.9 | 22.6 | 21.3 | 17.1 | |
Return on capital | % | 29.6 | 25.8 | 25.2 | 22.9 | 15.2 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 2.3 | 9.1 | 1.7 | 0.8 | 0.5 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 230 | 983 | 201 | 111 | 78 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx outflow | Rs m | 230 | 983 | 201 | 111 | 5,327 | |
Net fx | Rs m | -230 | -983 | -201 | -111 | -5,327 |
ERIS LIFESCIENCES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 2,230 | 2,712 | 3,754 | 3,783 | 2,917 | |
From Investments | Rs m | -51 | 1,232 | -3,234 | -3,196 | -9,821 | |
From Financial Activity | Rs m | -2,211 | -3,346 | -824 | -447 | 6,880 | |
Net Cashflow | Rs m | -31 | 598 | -304 | 140 | 52 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: Amit Indubhushan Bakshi | COMP SEC: Milind Talegaonkar | YEAR OF INC: 2007 | BSE CODE: 540596 | FV (Rs): 1 | DIV YIELD (%): 0.8 |
Read: ERIS LIFESCIENCES 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare ERIS LIFESCIENCES With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.